Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
With reference to the stock exchange announcement from December 1[st] 2023 which reported more than 75% patients recruited to the phase IIb clinical trial HeROPA, Arctic Bioscience is pleased to report that we have now fully recruited this phase IIb clinical trial in mild-to-moderate psoriasis with the planned 519 patients.
The HeROPA trial is randomized, double blind and placebo controlled, investigating the efficacy and safety of the novel, oral drug candidate HRO350 for the treatment of mild-to-moderate psoriasis. The HeROPA trial is ongoing in 5 countries in Europe; UK, Germany, Poland, Finland and Norway.
The HeROPA trial has had competitive recruitment at over 60 sites in the 5 countries to recruit the 519 patients. Fully recruiting this very large study is a result of impressive efforts from over 60 sites across five countries. The final recruited patients will be dosed in the next few weeks, and first data-readout will be when all patients have been treated for 6 months, mid 2024.
We are grateful for the participation of dermatology clinics and patients with mild-to-moderate psoriasis throughout Europe and the UK in the HeROPA study.
"We are very pleased to announce that our HeROPA clinical trial is now fully recruited. This is a major milestone for Arctic Bioscience and a result of great team effort by the employees in Arctic Bioscience, our CRO Smerud Medical Research International and the 60+ clinics participating in the trial. With this, we have taken another huge step forward in our medical program within mild-to-moderate psoriasis. After all patients have been dosed for 6 months, the primary endpoint will be read out." says CEO Christer L. Valderhaug.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.